RNA modifications in pulmonary diseases

Author:

Qian Weiwei12ORCID,Yang Lvying3,Li Tianlong4,Li Wanlin5,Zhou Jian67,Xie Shenglong8

Affiliation:

1. Emergency Department of Emergency Medicine Laboratory of Emergency Medicine, West China Hospital, And Disaster Medical, Sichuan University Chengdu Sichuan China

2. Emergency Department Shangjinnanfu Hospital, West China Hospital, Sichuan University Chengdu Sichuan China

3. The Department of Respiratory and Critical Care Medicine The First Veterans Hospital of Sichuan Province Chengdu Sichuan China

4. Department of Critical Care Medicine Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu Sichuan China

5. National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital Shenzhen Guangdong China

6. Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National‐Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical School Shenzhen China

7. Department of Immunology International Cancer Center, Shenzhen University Health Science Center Shenzhen Guangdong China

8. Department of Thoracic Surgery Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China Chengdu Sichuan China

Abstract

AbstractThreatening public health, pulmonary disease (PD) encompasses diverse lung injuries like chronic obstructive PD, pulmonary fibrosis, asthma, pulmonary infections due to pathogen invasion, and fatal lung cancer. The crucial involvement of RNA epigenetic modifications in PD pathogenesis is underscored by robust evidence. These modifications not only shape cell fates but also finely modulate the expression of genes linked to disease progression, suggesting their utility as biomarkers and targets for therapeutic strategies. The critical RNA modifications implicated in PDs are summarized in this review, including N6‐methylation of adenosine, N1‐methylation of adenosine, 5‐methylcytosine, pseudouridine (5‐ribosyl uracil), 7‐methylguanosine, and adenosine to inosine editing, along with relevant regulatory mechanisms. By shedding light on the pathology of PDs, these summaries could spur the identification of new biomarkers and therapeutic strategies, ultimately paving the way for early PD diagnosis and treatment innovation.

Funder

National Natural Science Foundation of China

Postdoctoral Research Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3